Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer

  • Authors:
    • Takayuki Kaburagi
    • Hiroaki Satoh
    • Kenji Hayashihara
    • Takeshi Endo
    • Nobuyuki Hizawa
    • Koichi Kurishima
    • Yoshihiro Nishimura
    • Toshio Hashimoto
    • Hiroyuki Nakamura
    • Koji  Kishi
    • Masaharu Inagaki
    • Takeshi Nawa
    • Hideo Ichimura
    • Hiroichi  Ishikawa
    • Katsunori Kagohashi
    • Toshihiko  Fukuoka
    • Yoko Shinohara
    • Koichi  Kamiyama
    • Yukio  Sato
    • Mitsuaki  Sakai
    • Takeshi Matsumura
    • Keiko Uchiumi
    • Kinya Furukawa
  • View Affiliations

  • Published online on: November 27, 2012     https://doi.org/10.3892/ol.2012.1048
  • Pages: 435-439
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To evaluate the efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), we performed a population-based observational study. The study involved 307 patients treated with erlotinib at 14 sites (17 departments) in Ibaraki (Japan) between December 2007 and December 2010. The tumor response and disease control rates were 11.1 and 46.3% in all patients, respectively. The median time to treatment failure and survival time were 1.6 months (95% confidence interval, 41‑57 days) and 5.3 months (134‑181 days) in all patients, respectively. Survival was significantly prolonged in EGFR mutation-positive patients compared with negative patients. EGFR mutation-negative patients who presented with a skin rash had significantly prolonged survival compared with those without a skin rash. The most common adverse event was skin disorder, followed by diarrhea. Although 45.6% of the patients in this study received erlotinib as a fourth-line or subsequent treatment, the results from this study were similar to those of clinical studies. We deduce that erlotinib is effective against NSCLC and is tolerated in clinical practice.
View Figures
View References

Related Articles

Journal Cover

February 2013
Volume 5 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kaburagi T, Satoh H, Hayashihara K, Endo T, Hizawa N, Kurishima K, Nishimura Y, Hashimoto T, Nakamura H, Kishi K, Kishi K, et al: Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer. Oncol Lett 5: 435-439, 2013
APA
Kaburagi, T., Satoh, H., Hayashihara, K., Endo, T., Hizawa, N., Kurishima, K. ... Furukawa, K. (2013). Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer. Oncology Letters, 5, 435-439. https://doi.org/10.3892/ol.2012.1048
MLA
Kaburagi, T., Satoh, H., Hayashihara, K., Endo, T., Hizawa, N., Kurishima, K., Nishimura, Y., Hashimoto, T., Nakamura, H., Kishi, K., Inagaki, M., Nawa, T., Ichimura, H., Ishikawa, H., Kagohashi, K., Fukuoka, T., Shinohara, Y., Kamiyama, K., Sato, Y., Sakai, M., Matsumura, T., Uchiumi, K., Furukawa, K."Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer". Oncology Letters 5.2 (2013): 435-439.
Chicago
Kaburagi, T., Satoh, H., Hayashihara, K., Endo, T., Hizawa, N., Kurishima, K., Nishimura, Y., Hashimoto, T., Nakamura, H., Kishi, K., Inagaki, M., Nawa, T., Ichimura, H., Ishikawa, H., Kagohashi, K., Fukuoka, T., Shinohara, Y., Kamiyama, K., Sato, Y., Sakai, M., Matsumura, T., Uchiumi, K., Furukawa, K."Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer". Oncology Letters 5, no. 2 (2013): 435-439. https://doi.org/10.3892/ol.2012.1048